NeoDynamics participates at EUSOBI, Europe’s most renowned congress for breast imaging
NeoDynamics today announces plans for EUSOBI, Annual Scientific Meeting 2022, in Malmö, Sweden. September 29 – October 1, 2022.
“EUSOBI provides an excellent opportunity for breast radiologists with a specialist interest in imaging, to learn about the latest developments in this field, as well as get hands-on-experience on the latest technology and approaches” said Anna Eriksrud, CEO.
The company recently received approval from the US Food and Drug Administration, which is a major milestone for the company. The focus on Europe is still very important for NeoDynamics, as it continues to challenge conventional approaches in breast imaging. EUSOBI is an excellent platform for NeoDynamics, to access and engage with key physicians in Europe. NeoDynamics will feature in this year’s programme offering a workshop for attendees, where they can use the device. It is this hands-on-experience which really highlights the benefits of the device to the user and patient.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
Aaron Wong, CFO NeoDynamics AB, phone +46 735 972 011 or e-mail aaron.wong@neodynamics.com
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients. NeoDynamic´s share is listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia received US approval from the US Food and Drug Administration, FDA, in September 2022.